2:55 PM
 | 
Sep 11, 2017
 |  BC Extra  |  Clinical News

Regeneron falls on Phase III asthma readout for Dupixent

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said Dupixent dupilumab met the co-primary endpoints in the Phase III LIBERTY ASTHMA QUEST trial to treat uncontrolled, persistent asthma. However, the data failed to impress investors as Regeneron fell $26.38 to $445.11 and lost more than $2.7 billion in market cap on Monday.

On the co-primary exacerbation endpoint, 300 mg Dupixent reduced the annual rate of severe asthma attacks at week 52 by 46% vs. placebo in the overall population (p<0.001). The prespecified primary analysis included a hierarchical evaluation of the endpoints in the overall population, in patients with 150...

Read the full 488 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >